Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses. Novo Nordisk's next-generation ...
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM. AbbVie and Iambic, a clinical-stage life ...
A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by ...
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...
FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...
Orbis Medicines announced a strategic collaboration and license agreement with Novo to discover and develop next-generation ...
Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...
Pharmaceutical Executive: What are the costly ways that RWD can impact clinical trial recruitment? Jen Lamppa: Two things ...
Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, ...
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results